Abstract

New series of thioquinoline structures bearing phenylacetamide 9ap were designed, synthesized and the structure of all derivatives was confirmed using different spectroscopic techniques including FTIR, 1H-NMR, 13C-NMR, ESI–MS and elemental analysis. Next, the α-glucosidase inhibitory activities of derivatives were also determined and all the synthesized compounds (IC50 = 14.0 ± 0.6–373.85 ± 0.8 μM) were more potent than standard inhibitors acarbose (IC50 = 752.0 ± 2.0 μM) against α-glucosidase. Structure–activity relationships (SARs) were rationalized by analyzing the substituents effects and it was shown that mostly, electron-donating groups at the R position are more favorable compared to the electron-withdrawing group. Kinetic studies of the most potent derivative, 9m, carrying 2,6-dimethylphenyl exhibited a competitive mode of inhibition with Ki value of 18.0 µM. Furthermore, based on the molecular dynamic studies, compound 9m depicted noticeable interactions with the α-glucosidase active site via several H-bound, hydrophobic and hydrophilic interactions. These interactions cause interfering catalytic potential which significantly decreased the α-glucosidase activity.

Details

Title
Synthesis, in vitro inhibitor screening, structure–activity relationship, and molecular dynamic simulation studies of novel thioquinoline derivatives as potent α-glucosidase inhibitors
Author
Forozan, RasaDokht 1 ; Ghomi, Minoo Khalili 2 ; Iraji, Aida 3 ; Montazer, Mohammad Nazari 2 ; Noori, Milad 4 ; Dastyafteh, Navid 4 ; Mojtabavi, Somayeh 5 ; Faramarzi, Mohammad Ali 5 ; Sadat-Ebrahimi, Seyed Esmaeil 1 ; Larijani, Bagher 2 ; Javanshir, Shahrzad 4 ; Mahdavi, Mohammad 2 

 Tehran University of Medical Sciences, Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
 Tehran University of Medical Sciences, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
 Shiraz University of Medical Sciences, Stem Cells Technology Research Center, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698); Shiraz University of Medical Sciences, Central Research Laboratory, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698) 
 Iran University of Science and Technology, Pharmaceutical and Heterocyclic Chemistry Research Laboratory, Department of Chemistry, Tehran, Iran (GRID:grid.411748.f) (ISNI:0000 0001 0387 0587) 
 Tehran University of Medical Sciences, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
Pages
7819
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2813776110
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.